Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRTX-100 in Chronic Lumbar Disc Disease
NCT04042844Phase 2Recruiting
- Sponsor
- BioRestorative Therapies
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BRTX-100 in lumbar disc disease (2 arms), sponsored by BioRestorative Therapies. Primary endpoints: Primary Safety Measures (Adverse Events and Serious Adverse Events) at Week 104, Visual Analog Scale for Pain at Week 52 and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
BRTX-100
03
Conditions
lumbar disc disease
Beyond the preview
Go deeper on NCT04042844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042844.